Momentum Bioscience

Momentum Bioscience is developing tests for the early detection of blood-borne microbial infections to accelerate the identification of patients with sepsis.

There is an urgent need to develop rapid tests for identifying bacteria or fungi in blood, allowing clinicians to make faster and better-informed antibiotic decisions, increasing the efficacy of therapies and improving antibiotic stewardship. The Company is using its proprietary ETGA (Enzyme Template Generation and Amplification) technology to develop a direct-from-blood test that runs in <3 hours, identifying the presence of an infection and its Gram classification up to 4 days earlier than most current tests.

Visit website